Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122095 | 0.90 | L3MBTL1 (0.42) | L3MBTL1ITGA4ITGB7CTSBATM | |
| SCHEMBL6706187 | 0.83 | ITGA4 (0.43) | L3MBTL1ITGA4ITGB7CTSBATM | |
| SCHEMBL11566665 | 0.83 | HDAC3 (0.41) | L3MBTL1ITGA4ITGB7CTSBATM | |
| SCHEMBL21683084 | 0.82 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL21683083 | 0.82 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL27166240 | 0.81 | ITGB3 (0.41) | L3MBTL1PPARA | |
| SCHEMBL23099848 | 0.80 | ATM (0.42) | L3MBTL1ITGA4ITGB7CTSBATM | |
| SCHEMBL8472423 | 0.80 | ALDH1A1 (0.48) | L3MBTL1ITGA4ITGB7ATMACE | |
| SCHEMBL10957821 | 0.80 | ATM (0.42) | L3MBTL1ITGA4ITGB7CTSBATM | |
| SCHEMBL8472422 | 0.80 | ALDH1A1 (0.48) | L3MBTL1ITGA4ITGB7ATMACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440109-B2 | Fullerene derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| EP-2495246-A1 | FULLERENE DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120216867-A1 | FULLERENE DERIVATIVES | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2448033-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | Sumitomo Chemical Company, Limited (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120091449-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110193073-A1 | FULLERENE DERIVATIVE, COMPOSITION AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110193072-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2345638-A1 | FULLERENE DERIVATIVE, COMPOSITION AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345651-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110001093-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110193073-A1 | FULLERENE DERIVATIVE, COMPOSITION AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | CCNE2, CTNNA1, CCNA1 | L3MBTL1 2713/4885ITGA4 582/4885ITGB7 1164/4885 |
| US-20110193072-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | C1S, CYP2S1, CCNE2 | L3MBTL1 2030/4885ITGA4 1078/4885ITGB7 1411/4885 |
| US-20110001093-A1 | FULLERENE DERIVATIVE | CCNE2, H1-0, CRY2 | L3MBTL1 680/4885ITGA4 256/4885ITGB7 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.